11 results about "Cancer cell" patented technology

The Body Cavity Cancer Treatment Apparatus generates the magnetic field for use in a combined “Low Temperature Hyperthermia” and ionizing radiation and/or chemotherapy cancer treatment protocol. Unlike other competing systems, the Body Cavity Cancer Treatment Apparatus does not directly kill or ablate the cancer cells with killing temperatures rather, the Body Cavity Cancer Treatment Apparatus stresses the cancer and cancer stem cells by keeping them at a nominal 42° Celsius for some period of time via the heating of nano-particles that have been infused into the bladder, using the generated magnetic field.

The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification. The method is exemplified herein and therefore provides compositions and methods for inducing an immune response against gp 100 melanoma cells and for inducing an immune response against HER-2+cells. Cancer vaccines and adoptive immunotherapeutic methods to treat and prevent conditions associated with the presence of these cells in a subject also are provided. The methods can be practiced by administering the appropriate gene or cancer vaccine, antibody, protein, polypeptide, antigen-presenting cell or immune effector cell.

The invention provides a polyethylene glycol-polyamide-amine-polyamino acid linear-dendritic block polymer with a structure shown as a formula I, II, III or IV. The polyethylene glycol in the block polymer can be used for improving the biocompatibility of the block polymer and prolonging the circulation time of the block polymer in the blood, and a polyamino acid block can be used for ensuring the favorable degradation performance of a product and can be discharged in vitro after being degraded in vivo. The block polymer provided by the invention is simple in preparation method and safe and nontoxic in product. The block polymer is used as a carrier and assembled in water to form nanoparticles, and a model drug adriamycin is carried, so that drug-carried nanoparticles are obtained, and the drug-carried nanoparticles have a certain controlled-release function and can be used for effectively inhibiting the proliferation of cancer cells in cell experiments. Therefore, the block polymer has the potential application as a nano-drug carrier.

It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.

The invention discloses a preparation method of zif-8 nanosphere loaded SERS coded gold nanoparticles for intracellular photothermal therapy. The preparation method comprises the following specific steps: (1) reacting chloroauric acid with trisodium citrate to generate 13nm gold nanoparticles; (2) labeling gold nanoparticles by using a Raman reporter DTTC, and adding sulfydryl-containing polyethylene glycol to stabilize the gold nanoparticles; (3) adding polyethylene glycol with a sulfydryl group at one end and a carboxyl group at the other end into (2), modifying the surfaces of the gold nanoparticles with a large amount of carboxyl groups, adding adriamycin and an activating agent, and reacting the materials for 24 hours to obtain drug-loaded gold nanoparticles; and (4) dispersing the drug-loaded gold nanoparticles in the step (3) into zinc nitrate and ligand dimethylimidazole, and reacting the materials to obtain the zif-8 nanosphere loaded SERS coded gold nanoparticles. The SERS coded drug-loaded nanoparticles prepared by the invention can be used for inhibiting cell transfer and intracellular photothermal therapy, and the drug is loaded on the surfaces of the gold nanoparticles to realize internalization of the drug and kill cancer cells to the maximum extent.

The invention discloses a wild ganoderma product for resisting cancer and tumor and removing liver toxin and a preparation technology. According to the invention, wild ganoderma lucidum is adopted asraw material, and the wild ganoderma product for resisting cancer and tumor and removing liver toxin is finally prepared by the steps of washing, sterilizing, drying and dicing and the like. The product has the advantages of inhibiting cancer cell growth, attending acute and chronic hepatitis, early cirrhosis, esophageal cancer, lung cancer, liver cancer, nasopharyngeal carcinoma, pancreatic cancer, neurasthenia, intestinal diarrhea, rheumatoid tuberculosis,diabetes, gastrointestinal diseases, nourishing physical, lowering blood sugar, moistening the lungs and kidneys, maintaining beauty and keeping young, enhancing immunity, and enriches in ergosterol, ganoderic acid, ganoderma lucidum polysaccharides, amino acids, polypeptides, adenosine, triterpenoids and various trace elements, whereinthe organic germanium content is as high as 12380 ppm and the organic selenium content is also high. The product can be made into five-color ganoderma lucidum tea, ganoderma lucidum beverage, ganoderma lucidum oral liquid, five-color ganoderma lucidum wine, and other homologous products of medicines and foods. The product provided by the invention can also be made into traditional Chinese medicine prescriptions such as paste, pill and pellet.

The invention relates to C-9 conjugated sialic acid and application thereof, and relates to sialic acid. The C-9 conjugated sialic acid (FOO-Sia) is prepared from fluorine (F)-oxygenous (O) fusion heterocyclic substitutional groups and sialic acid (Sia). The molecular formula of the C-9 conjugated sialic acid (FOO-Sia) is C23H25FN2O11; the molecular weight is 524.4544. The C-9 conjugated sialic acid (FOO-Sia) can be applied to cancer cell migration inhibition. The C-9 conjugated sialic acid (FOO-Sia) can be expressed onto the surface of the tumor cells in a covalent connection mode as a macrophage Siglec-1 combination ligand for mediating the tumor immunity killing and transferring inhibition.

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.

The invention relates to the new applications of an annonaceous acetogenins compound V, in particular to the applications of the compound V for preparing an anti-cancer drug. Annonaceous acetogenins is extracted from the scratch stock of a custard apple seed with organic solvent, including ethanol, petroleum ether, ethyl acetate and chloroform, etc.; the annonaceous acetogenins is processed by silicagel column chromatography and eluted with chloroform-methanol, petroleum ether-ethyl acetate and ethyl-acetate-methanol; and the annonaceous acetogenins compound V is made. The content of the annonaceous acetogenins compound V is 50 to 90 percent of mass fraction. An endozoic anti-cancer pharmacological test shows that the annonaceous acetogenins compound V has a significant effect on inhibiting the growth of the cancer cells of a lung, a breast and a liver and the anti-cancer activity of the annonaceous acetogenins compound V is higher than chemo-treatment 5-S-Fu, so the annonaceous acetogenins compound V can be used for preparing the anti-cancer drug.

The invention provides a photo-thermal preparation based on a selenium nanosheet. The photo-thermal preparation based on the selenium nanosheet comprises the selenium nanosheet, and polyethylene glycol attached to the selenium nanosheet, wherein the selenium nanosheet has a good photo-thermal conversion rate, and cancer cells are killed by utilizing local high temperature generated by the seleniumnanosheet under the irradiation of near-infrared laser, so that the effect of photo-thermal tumor treatment is achieved. Polyethylene glycol is attached to the surface of the selenium nanosheet, andhydrogen bonds are formed between hydroxyl on the surface of polyethylene glycol and an aqueous solution, so that the photo-thermal preparation based on the selenium nanosheet can be better promoted to be dissolved in the aqueous solution, and the advantages of being good in compatibility, high in stability and the like are achieved. The invention further provides a preparation method and application of the photo-thermal preparation based on the selenium nanosheet.

The invention discloses cucumber exosome-like vesicles containing cucurbitacin B and capable of being used as anti-cancer drugs. Cucurbitacin B can be used for inhibiting proliferation of various cancer cells, but an extraction method of cucurbitacin B is complex and time-consuming. The method of separating the cucumber exosome-like vesicles to obtain cucurbitacin B has the advantages of easinessand quickness in operation and the like, and the lipid bilayer of the exosome-like vesicles is used as a natural protective film of cucurbitacin B, so that the stability of cucurbitacin B can be maintained for a long time. Moreover, through the principle of similarity and intermiscibility, the intake rate of cells to cucurbitacin B is also improved to a certain extent due to the existence of the lipid bilayer. When the cucumber exosome-like vesicles act on human alveolar basal epithelial cells (A549 cells) of adenocarcinoma, the maximum cell activity inhibition rate of the cucumber exosome-like vesicles is twice that of a cucurbitacin B standard substance, the dosage is lower, the toxicity to normal cells and the drug resistance to cancer cells can be reduced, and the cucumber exosome-likevesicles have good anti-cancer potential and industrialization prospect, and have an important significance in the clinical tumor treatment application.